FDA-approved · Cash-pay · Ships to your door
Wegovy®
Access FDA-approved Wegovy® (semaglutide) through a US-licensed clinician if it's right for you. Reviewed online, prescribed when clinically appropriate, shipped to your door.
Medication, if prescribed
Wegovy®
$1,349/mo
Cash-pay; not billed to insurance
If a clinician decides treatment isn't right for you, you're refunded in full.
Wegovy® is the FDA-approved product from Novo Nordisk A/S, dispensed cash-pay through a US-licensed pharmacy. Pricing reflects pharmacy cash-pay rates and may change. A prescription is at the discretion of a US-licensed clinician.
- FDA-approved for chronic weight management in eligible adults
- Once-weekly subcutaneous pen injection
- Reviewed online and shipped from a US-licensed pharmacy
- Flat cash-pay pricing — no insurance billing or surprise fees
Wegovy® is the FDA-approved semaglutide product from Novo Nordisk A/S, indicated for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbidity. It's a once-weekly subcutaneous injection that works by mimicking the body's GLP-1 hormone — reducing appetite and slowing gastric emptying.
The easiest way to find out is to start. Our US-licensed provider partners review a short online intake — usually just a few minutes — and determine what's right for you on an individual basis, based on your health history and goals. There's no cost to find out and no obligation.
Yes. Shipping is always free, and every order arrives in plain, unmarked packaging from a US-licensed pharmacy — no one needs to know what's inside. Most orders arrive within about a week of approval.
Yes. Pallas is a cash-pay medical service, and we provide an itemized receipt for your visit and prescription that you can submit to your FSA or HSA. Most plans treat prescription medications and telehealth visits as eligible expenses — your plan administrator can confirm what applies to you.
About
What is Wegovy®?
Wegovy® is the FDA-approved semaglutide product from Novo Nordisk A/S, indicated for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbidity. It's a once-weekly subcutaneous injection that works by mimicking the body's GLP-1 hormone — reducing appetite and slowing gastric emptying.
Pallas dispenses Wegovy® through US-licensed pharmacies on a cash-pay basis. Insurance routing is not currently supported. Eligibility is determined by a licensed clinician based on your intake and clinical history.
Pivotal trial · STEP-1
Participants on Wegovy® lost an average of ~14.9% of body weight at 68 weeks alongside lifestyle intervention.
Source: New England Journal of Medicine, 2021. Outcome reflects the cited trial of the FDA-approved product and the conditions studied. Individual results may differ.
Dosing
Dosing & schedule
Wegovy® follows a 16-week dose-escalation schedule designed to minimize side effects as your body adjusts. Your clinician may modify the cadence based on your tolerability.
- Weeks 1–40.25 mg once weekly — starting dose
- Weeks 5–80.5 mg once weekly
- Weeks 9–121.0 mg once weekly
- Weeks 13–161.7 mg once weekly
- Week 17+2.4 mg once weekly — maintenance dose
Safety
Important safety information
GLP-1 medications can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and — based on animal studies — a possible risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications. Always disclose your full medical history to your clinician. Wegovy®'s full FDA-approved prescribing information, including its boxed warning, is available from Novo Nordisk and at the link below.
FAQ
Common questions
The easiest way to find out is to start. Our US-licensed provider partners review a short online intake — usually just a few minutes — and determine what's right for you on an individual basis, based on your health history and goals. There's no cost to find out and no obligation.
Yes. Shipping is always free, and every order arrives in plain, unmarked packaging from a US-licensed pharmacy — no one needs to know what's inside. Most orders arrive within about a week of approval.
Yes. Pallas is a cash-pay medical service, and we provide an itemized receipt for your visit and prescription that you can submit to your FSA or HSA. Most plans treat prescription medications and telehealth visits as eligible expenses — your plan administrator can confirm what applies to you.
We'll make it right. Pallas includes unlimited customer support — if anything's off with your shipment, or you simply have a question about your treatment, our support team and your care team are a message away, as often as you need, at no extra cost.
Pallas is cash-pay and doesn't bill insurance directly — that keeps your pricing simple and predictable. But because you receive the genuine, FDA-approved product with an itemized receipt, some patients choose to submit a claim to their insurer afterward for possible out-of-network reimbursement. Whether it's reimbursed is up to your individual plan.
Wegovy® is the brand name for the FDA-approved semaglutide injection manufactured by Novo Nordisk for chronic weight management. It's a once-weekly subcutaneous injection delivered via a single-dose pen.
All three are FDA-approved GLP-1 medications, but with different active ingredients, indications, and dosing. Wegovy® and Ozempic® both contain semaglutide (made by Novo Nordisk), but Wegovy® is FDA-approved for weight management while Ozempic® is FDA-approved for type 2 diabetes. Zepbound® contains a different molecule — tirzepatide, made by Eli Lilly — and is FDA-approved for weight management.
Wegovy® is $1,349/month on Pallas, billed flat with no insurance routing. The price covers a 28-day supply shipped directly from a US-licensed pharmacy. Pricing reflects pharmacy cash-pay rates and may change.
Yes — no contracts and no lock-in. You can pause or cancel your plan anytime, right from your patient portal.
Disclosures
Wegovy® is a registered trademark of Novo Nordisk A/S. The trademark owner is not affiliated with, a sponsor of, or an endorser of Pallas. Pallas dispenses the FDA-approved product cash-pay through a US-licensed pharmacy network; it is not billed to insurance. Eligibility and any prescription are determined by a US-licensed clinician.
Start your visit